Background/Aims: Cerebral microbleeds (CMBs) may predict the occurrence of intracerebral hemorrhage (ICH). Warfarin use may cause ICH. It is still controversial whether warfarin increases CMBs in atrial fibrillation (AF) patients. The study aimed to investigate the prevalence of CMBs and risk factors in AF patient population. Methods: This single retrospective center study included 113 patients with nonvalvular atrial fibrillation (NVAF) who were on outpatient treatment. CMBs were counted using 3D-enhanced T2*-weighted angiography (ESWAN) imaging. We compared clinical and radiological data between patients who used warfarin and not used warfarin with univariate analysis. The associations between clinical and radiological data and CMBs in NVAF population were analyzed with multivariate linear regression analyses. Results: Among 113 NVAF patients, CMBs were found in 33 (29.2%) patients; there were 53 patients who used warfarin for thromboembolism prevention and 60 patients with similar demographic features who did not use warfarin. CMBs on ESWAN MRI showed no significant difference between the 2 groups (p = 0.061). Patients with CMBs were older than patients without CMBs (p = 0.046), and the frequency of smokers (p = 0.028), hypertension (p = 0.029), previous ICH (p = 0.000), and leukoaraiosis (p = 0.020) in patients with CMBs were significantly higher than patients without CMBs. In multivariate linear regression analyses, previous ICH (β = 1.438, p = 0.000), age (β = 0.082, p = 0.000), hypertension (β = 0.956 p = 0.003), warfarin treatment (β = 0.849, p = 0.006), and smokers (β = 0.920, p = 0.016) were positive linear predictors of CMBs number levels in NVAF patients. Conclusion: The present data demonstrated that CMBs were associated with age, hypertension, warfarin treatment, smoking, and a history of ICH. We also found neither CHA2DS2-VASc score nor HAS-BLED score was associated with CMBs in patients with NVAF.

Keywords:
Atrial fibrillation, Cerebral microbleeds, Warfarin, 3D-enhanced T2*-weighted angiography, Prevalence
1.
Lip GY. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis.
J Thromb Haemost
. 2011 Jul;9(Suppl 1):344–51.
2.
Patel T, Patel V. Review: DOACs reduce intracranial hemorrhage more than warfarin in AF with CKD.
Ann Intern Med
. 2018 Feb;168(4):JC18.
3.
Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages.
Am J Med
. 2007 Aug;120(8):700–5.
4.
Conijn MM, Hoogduin JM, van der Graaf Y, Hendrikse J, Luijten PR, Geerlings MI. Microbleeds, lacunar infarcts, white matter lesions and cerebrovascular reactivity – a 7 T study.
Neuroimage
. 2012 Jan;59(2):950–6.
5.
Kleinig TJ. Associations and implications of cerebral microbleeds.
J Clin Neurosci
. 2013 Jul;20(7):919–27.
6.
Fazekas F, Kleinert R, Roob G, Kleinert G, Kapeller P, Schmidt R, et al. Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds.
AJNR Am J Neuroradiol
. 1999 Apr;20(4):637–42.
7.
Guo LF, Wang G, Zhu XY, Liu C, Cui L. Comparison of ESWAN, SWI-SPGR, and 2D T2*-weighted GRE sequence for depicting cerebral microbleeds.
Clin Neuroradiol
. 2013 Jun;23(2):121–7.
8.
Renard D. Cerebral microbleeds: a magnetic resonance imaging review of common and less common causes.
Eur J Neurol
. 2018 Mar;25(3):441–50.
9.
Sulch D. Warfarin use in patients with atrial fibrillation. May increase risk of haemorrhage in elderly patients.
BMJ
. 1997 Sep;315(7110):750; author reply 751.
10.
Fan YH, Zhang L, Lam WW, Mok VC, Wong KS. Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke.
Stroke
. 2003 Oct;34(10):2459–62.
11.
Greenberg SM, Eng JA, Ning M, Smith EE, Rosand J. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage.
Stroke
. 2004 Jun;35(6):1415–20.
12.
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
Chest
. 2010 Nov;138(5):1093–100.
13.
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.
Chest
. 2010 Feb;137(2):263–72.
14.
Nandigam RN, Viswanathan A, Delgado P, Skehan ME, Smith EE, Rosand J, et al. MR imaging detection of cerebral microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strength.
AJNR Am J Neuroradiol
. 2009 Feb;30(2):338–43.
15.
Gregoire SM, Jäger HR, Yousry TA, Kallis C, Brown MM, Werring DJ. Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage: hospital-based, case-control study.
J Neurol Neurosurg Psychiatry
. 2010 Jun;81(6):679–84.
16.
Mitaki S, Nagai A, Oguro H, Yamaguchi S. Serum Lipid Fractions and Cerebral Microbleeds in a Healthy Japanese Population.
Cerebrovasc Dis
. 2017;43(3-4):186–91.
17.
Chung CP, Chou KH, Chen WT, Liu LK, Lee WJ, Huang AC, et al. Location of Cerebral Microbleeds And Their Association with Carotid Intima-media Thickness: A Community-based Study.
Sci Rep
. 2017 Sep;7(1):12058.
18.
Vernooij MW, van der Lugt A, Ikram MA, Wielopolski PA, Niessen WJ, Hofman A, et al. Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study.
Neurology
. 2008 Apr;70(14):1208–14.
19.
Koennecke HC. Cerebral microbleeds on MRI: prevalence, associations, and potential clinical implications.
Neurology
. 2006 Jan;66(2):165–71.
20.
Saito T, Kawamura Y, Tanabe Y, Asanome A, Takahashi K, Sawada J, et al. Cerebral microbleeds and asymptomatic cerebral infarctions in patients with atrial fibrillation.
J Stroke Cerebrovasc Dis
. 2014 Jul;23(6):1616–22.
21.
Horstmann S, Möhlenbruch M, Wegele C, Rizos T, Laible M, Rauch G, et al. Prevalence of atrial fibrillation and association of previous antithrombotic treatment in patients with cerebral microbleeds.
Eur J Neurol
. 2015 Oct;22(10):1355–62.
22.
Charidimou A, Shams S, Romero JR, Ding J, Veltkamp R, Horstmann S, et al.; International META-MICROBLEEDS Initiative. Clinical significance of cerebral microbleeds on MRI: A comprehensive meta-analysis of risk of intracerebral hemorrhage, ischemic stroke, mortality, and dementia in cohort studies (v1).
Int J Stroke
. 2018 Jul;13(5):454–68.
23.
Barnaure I, Montandon ML, Rodriguez C, Herrmann F, Lövblad KO, Giannakopoulos P, et al. Clinicoradiologic Correlations of Cerebral Microbleeds in Advanced Age.
AJNR Am J Neuroradiol
. 2017 Jan;38(1):39–45.
24.
Charidimou A, Imaizumi T, Moulin S, Biffi A, Samarasekera N, Yakushiji Y, et al. Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: A meta-analysis.
Neurology
. 2017 Aug;89(8):820–9.
25.
Graff-Radford J, Simino J, Kantarci K, Mosley TH Jr, Griswold ME, Windham BG, et al. Neuroimaging Correlates of Cerebral Microbleeds: The ARIC Study (Atherosclerosis Risk in Communities).
Stroke
. 2017 Nov;48(11):2964–72.
26.
Poels MM, Vernooij MW, Ikram MA, Hofman A, Krestin GP, van der Lugt A, et al. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study.
Stroke
. 2010 Oct;41(10 Suppl):S103–6.
27.
Jia Z, Mohammed W, Qiu Y, Hong X, Shi H. Hypertension increases the risk of cerebral microbleed in the territory of posterior cerebral artery: a study of the association of microbleeds categorized on a basis of vascular territories and cardiovascular risk factors.
J Stroke Cerebrovasc Dis
. 2014 Jan;23(1):e5–11.
28.
Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges.
Lancet Neurol
. 2010 Jul;9(7):689–701.
29.
Lei C, Lin S, Wu B, Li H, Liu M, You C. Lipid levels are regionally associated with cerebral microbleeds in patients with intracerebral hemorrhage.
J Stroke Cerebrovasc Dis
. 2014 May-Jun;23(5):1195–8.
30.
Roob G, Lechner A, Schmidt R, Flooh E, Hartung HP, Fazekas F. Frequency and location of microbleeds in patients with primary intracerebral hemorrhage.
Stroke
. 2000 Nov;31(11):2665–9.
31.
Shoamanesh A, Kwok CS, Benavente O. Cerebral microbleeds: histopathological correlation of neuroimaging.
Cerebrovasc Dis
. 2011;32(6):528–34.
32.
Charidimou A, Shakeshaft C, Werring DJ. Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk.
Front Neurol
. 2012 Sep;3:133.
33.
Lovelock CE, Cordonnier C, Naka H, Al-Shahi Salman R, Sudlow CL; Edinburgh Stroke Study Group, Sorimachi T, Werring DJ, Gregoire SM, Imaizumi T, Lee SH, Briley D, Rothwell PM. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies.
Stroke
. 2010 Jun;41(6):1222-8.
34.
Orken DN, Uysal E, Timer E, Kuloglu-Pazarcı N, Mumcu S, Forta H. New cerebral microbleeds in ischemic stroke patients on warfarin treatment: two-year follow-up.
Clin Neurol Neurosurg
. 2013 Sep;115(9):1682–5.
35.
Saito T, Kawamura Y, Sato N, Kano K, Takahashi K, Asanome A, et al. Non-vitamin k antagonist oral anticoagulants do not increase cerebral microbleeds.
J Stroke Cerebrovasc Dis
. 2015 Jun;24(6):1373–7.
36.
Saito T, Kawamura Y, Sato N, Sugiyama E, Okada M, Takeuchi T, et al. Cerebral Microbleeds Remain for Nine Years: A Prospective Study with Yearly Magnetic Resonance Imaging.
J Stroke Cerebrovasc Dis
. 2018 Feb;27(2):315–20.
37.
Spijkerman AM, van der A DL, Nilsson PM, Ardanaz E, Gavrila D, Agudo A, et al.; InterAct Consortium. Smoking and long-term risk of type 2 diabetes: the EPIC-InterAct study in European populations.
Diabetes Care
. 2014 Dec;37(12):3164–71.
38.
Virdis A, Giannarelli C, Neves MF, Taddei S, Ghiadoni L. Cigarette smoking and hypertension.
Curr Pharm Des
. 2010;16(23):2518–25.
39.
Nordahl H, Osler M, Frederiksen BL, Andersen I, Prescott E, Overvad K, et al. Combined effects of socioeconomic position, smoking, and hypertension on risk of ischemic and hemorrhagic stroke.
Stroke
. 2014 Sep;45(9):2582–7.
40.
Del Brutto VJ, Zambrano M, Mera RM, Del Brutto OH. Population-Based Study of Cerebral Microbleeds in Stroke-Free Older Adults Living in Rural Ecuador: The Atahualpa Project.
Stroke
. 2015 Jul;46(7):1984–6.
41.
Power MC, Deal JA, Sharrett AR, Jack CR Jr, Knopman D, Mosley TH, et al. Smoking and white matter hyperintensity progression: the ARIC-MRI Study.
Neurology
. 2015 Feb;84(8):841–8.
42.
Kim MH, Moon JS, Park SY, An SA, Kim OJ, Kim NK, et al. Different risk factor profiles between silent brain infarction and symptomatic lacunar infarction.
Eur Neurol
. 2011;65(5):250–6.
43.
Imaizumi T, Inamura S, Nomura T. Contribution of Deep Microbleeds to Stroke Recurrence: Differences between Patients with Past Deep Intracerebral Hemorrhages and Lacunar Infarctions.
J Stroke Cerebrovasc Dis
. 2015 Aug;24(8):1855–64.
44.
Kim BJ, Lee SH. Cerebral microbleeds: their associated factors, radiologic findings, and clinical implications.
J Stroke
. 2013 Sep;15(3):153–63.
45.
Saba L, Raz E, Bassareo PP, di Martino M, de Cecco CN, Mercuro G, et al. Is there an association between cerebral microbleeds and leukoaraiosis?
J Stroke Cerebrovasc Dis
. 2015 Feb;24(2):284–9.
46.
Zhang C, Li Z, Wang Y, Zhao X, Wang C, Liu L, et al.; Chinese IntraCranial AtheroSclerosis (CICAS) Study Group. Risk factors of cerebral microbleeds in strictly deep or lobar brain regions differed.
J Stroke Cerebrovasc Dis
. 2015 Jan;24(1):24–30.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.